(JREE) JPMorgan s (Ireland) ICAV - Ratings and Ratios
European, Large-Cap, Equities, Exchange-Traded Fund, Morningstar Index
Description: JREE JPMorgan s (Ireland) ICAV
The JPMorgan ETFs (Ireland) ICAV - Europe Research Enhanced Index Equity UCITS ETF - EUR (acc) EUR, traded as JREE on the Swiss market, is an exchange-traded fund that tracks the Morningstar Developed Markets Europe TME NR EUR Index. This ETF is designed to provide investors with exposure to large-cap European equities, blending growth and value stocks.
As a Europe Large-Cap Blend Equity ETF, JREE invests in a diversified portfolio of European companies, aiming to replicate the performance of its underlying index. The funds investment strategy is based on a research-enhanced index approach, which combines quantitative and qualitative insights to optimize returns.
With Assets Under Management (AUM) of approximately €47.183 billion, JREE is one of the larger ETFs in its category, indicating a significant investor interest in European large-cap equities. This substantial AUM also suggests that the fund is well-established and has a certain level of liquidity.
Analyzing the technical data, we observe that the ETFs last price is €46.45, with a 20-day Simple Moving Average (SMA) of €46.04, indicating a recent uptrend. The 50-day SMA (€44.54) and 200-day SMA (€43.79) further support this bullish trend, as the short-term SMAs are above the longer-term SMAs. The Average True Range (ATR) of €0.33 (0.71%) suggests moderate volatility.
Using the available technical and fundamental data, we can forecast that JREE may continue its upward trend, driven by the overall European equity market performance. If the ETF maintains its current momentum, it may reach the upper end of its 52-week range (€47.13) or potentially break through it, given the right market conditions. Conversely, a decline below the 50-day SMA (€44.54) could indicate a reversal in the trend. Investors should monitor the ETFs price action and adjust their strategies accordingly.
To make an informed investment decision, its essential to consider both the macroeconomic outlook for European equities and the specific characteristics of the JREE ETF. A thorough analysis of the underlying index, the funds holdings, and the overall market conditions will help investors determine whether JREE aligns with their investment objectives and risk tolerance.
Additional Sources for JREE ETF
JREE ETF Overview
Market Cap in USD | 55,671m |
Category | Europe Large-Cap Blend Equity |
IPO / Inception | 2018-10-10 |
JREE ETF Ratings
Growth Rating | 55.4 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -8.82 |
Analysts | - |
Fair Price Momentum | 44.05 EUR |
Fair Price DCF | - |
JREE Dividends
Currently no dividends paidJREE Growth Ratios
Growth Correlation 3m | 66.7% |
Growth Correlation 12m | 54.4% |
Growth Correlation 5y | 91.4% |
CAGR 5y | 27.38% |
CAGR/Max DD 5y | 1.67 |
Sharpe Ratio 12m | 1.43 |
Alpha | -4.77 |
Beta | 0.530 |
Volatility | 11.65% |
Current Volume | 20.1k |
Average Volume 20d | 0.8k |
As of July 04, 2025, the stock is trading at EUR 45.34 with a total of 20,120 shares traded.
Over the past week, the price has changed by +0.22%, over one month by -1.56%, over three months by +3.48% and over the past year by +5.09%.
Partly, yes. Based on ValueRay´s Analyses, JPMorgan s (Ireland) ICAV (SW:JREE) is currently (July 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 55.44 and therefor an somewhat technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JREE is around 44.05 EUR . This means that JREE is currently overvalued and has a potential downside of -2.85%.
JPMorgan s (Ireland) ICAV has no consensus analysts rating.
According to our own proprietary Forecast Model, JREE JPMorgan s (Ireland) ICAV will be worth about 49.6 in July 2026. The stock is currently trading at 45.34. This means that the stock has a potential upside of +9.4%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 49.6 | 9.4% |